Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:S115-S120
doi: 10.1161/CIRCULATIONAHA.107.756049
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ota, T.
Right arrow Articles by Zenati, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ota, T.
Right arrow Articles by Zenati, M. A.
Related Collections
Right arrow Other heart failure
Right arrow Other Treatment
Right arrow CV surgery: other

(Circulation. 2008;118:S115-S120.)
© 2008 American Heart Association, Inc.


Cell Transplantation and Tissue Regeneration

Minimally Invasive Epicardial Injections Using a Novel Semiautonomous Robotic Device

Takeyoshi Ota, MD, PhD; Nicholas A. Patronik, PhD; David Schwartzman, MD; Cameron N. Riviere, PhD; Marco A. Zenati, MD

From the Division of Cardiac Surgery (T.O., M.A.Z.) and the Cardiovascular Institute (D.S.), University of Pittsburgh, Pittsburgh, Pa; and The Robotics Institute (N.A.P., C.N.R., M.A.Z.), Carnegie Mellon University, Pittsburgh, Pa.

Correspondence to Marco A. Zenati, MD, Professor of Surgery and Biomedical Engineering, Division of Cardiac Surgery, University of Pittsburgh, 200 Lothrop Street, PUH C-700, Pittsburgh, PA 15213. E-mail zenatim{at}upmc.edu

Background— We have developed a novel miniature robotic device (HeartLander) that can navigate on the surface of the beating heart through a subxiphoid approach. This study investigates the ability of HeartLander to perform in vivo semiautonomous epicardial injections on the beating heart.

Methods and Results— The inchworm-like locomotion of HeartLander is generated using vacuum pressure for prehension of the epicardium and drive wires for actuation. The control system enables semiautonomous target acquisition by combining the joystick input with real-time 3-dimensional localization of the robot provided by an electromagnetic tracking system. In 12 porcine preparations, the device was inserted into the intrapericardial space through a subxiphoid approach. Ventricular epicardial injections of dye were performed with a custom injection system through HeartLander’s working channel. HeartLander successfully navigated to designated targets located around the circumference of the ventricles (mean path length=51±25 mm; mean speed=38±26 mm/min). Injections were successfully accomplished following the precise acquisition of target patterns on the left ventricle (mean injection depth=3.0±0.5 mm). Semiautonomous target acquisition was achieved within 1.0±0.9 mm relative to the reference frame of the tracking system. No fatal arrhythmia or bleeding was noted. There were no histological injuries to the heart due to the robot prehension, locomotion, or injection.

Conclusions– In this proof-of-concept study, HeartLander demonstrated semiautonomous, precise, and safe target acquisition and epicardial injection on a beating porcine heart through a subxiphoid approach. This technique may facilitate minimally invasive cardiac cell transplantation or polymer therapy in patients with heart failure.


Key Words: computers • heart failure • minimally invasive robotic surgery • myocardium